IP Library Granted Patent US 8,163,275
Granted Patent B2
US 8,163,275 · App. 12/573,652 · Granted Apr 24, 2012

Multi-lineage progenitor cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,275
App. No.
12/573,652
Granted
Apr 24, 2012
Kind
B2
Abstract

Fetal blood multi-lineage progenitor cells that are capable of a wide spectrum of transdifferentiation are described.

Claims (15)

1. A method for obtaining a population of multi-lineage progenitor cells (MLPC) having a fibroblast morphology, said method comprising:

a) contacting a human fetal blood sample with a composition, said composition comprising:

i) dextran;

ii) anti-glycophorin A antibody;

iii) anti-CD15 antibody; and

iv) anti-CD9 antibody;

b) allowing said sample to partition into an agglutinate and a supernatant phase;

c) recovering cells from said supernatant phase;

d) purifying MLPC from the recovered cells by adherence to a solid substrate, wherein said MLPC are positive for CD9 and positive for CD45; and

e) culturing said MLPC such that said MLPC obtain said fibroblast morphology, wherein said MLPC, after obtaining said fibroblast morphology, are positive for CD9, CD13, CD29, CD44, CD73, CD90, and CD105, and negative for CD10, CD34, CD41, CD45, Stro-1, stage-specific embryonic antigen-3 (SSEA-3), and stage-specific embryonic antigen-4 (SSEA-4).

2. The method of claim 1 , wherein said fetal blood sample is cord blood.

3. The method of claim 1 , wherein said solid substrate is a plastic substrate.

4. The method of claim 1 , wherein said MLPC, after obtaining said fibroblast morphology, are further negative for CD2, CD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD19, CD20, CD22, CD33, CD36, CD38, CD61, CD62E, CD133, glycophorin-A, stem cell factor, and human leukocyte antigen (HLA)-DR.

5. The method of claim 1 , further comprising testing said MLPC for CD9.

6. The method of claim 5 , further comprising testing said MLPC for CD29, CD45, CD73, and CD90.

Assignments (2)
CHANGE OF NAME Recorded Aug 12, 2010
From: BI ACQUIRING LLC
To: BIOE LLC
Reel/Frame 024823/0422 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2010
From: BIOE, INC.
To: BI ACQUIRING LLC
Reel/Frame 024794/0593 →